ShangBay Capital Research
Investment Thesis
ShangBay Capital is a Palo Alto-based venture capital firm dedicated exclusively to healthcare, with a sharp specialization in medical devices and biopharma. The firm partners with founders building disruptive companies that address high, unmet clinical needs, and describes its approach as collaborative: working closely with entrepreneurs, leveraging a deep operator and clinician network, and drawing on FDA regulatory-pathway expertise to help portfolio companies navigate the path to approval and commercialization. Founded in 2015, the firm has built one of the most active track records in medtech investing over the past decade.
Sector Focus
ShangBay invests exclusively within healthcare, spanning:
- Medical devices (cardiovascular, neurology, surgical robotics, diagnostics, women's health)
- Biopharma and biotech therapeutics
- Digital and AI-enabled healthcare tools (e.g., AI-powered diagnostics, brain-monitoring platforms)
The portfolio shows deep concentration in cardiovascular devices, neurostimulation, oncology/immunology biotech, and surgical robotics, with a smaller but growing set of AI-native diagnostic companies.
Stage Focus
Evidence from the portfolio and recent financings shows ShangBay investing across a wide stage range, from early Series A financings through late-stage growth rounds (Series C-E) and pre-IPO positions. The firm is not a pure seed investor; its typical entry point appears to be Series A/B, with continued participation through growth rounds and public offerings.
Check Size
Check size is not publicly disclosed. Round sizes ShangBay has participated in range from roughly $22M (Series A/C rounds) to $78M+ (Series E), implying meaningful check sizes for a specialist healthcare fund, likely in the single-digit to low-double-digit millions per round with reserves for follow-ons.
Lead Tendency
ShangBay both leads and follows. It led Avation Medical's oversubscribed $22M+ Series C alongside Asahi Kasei (Feb 2024), and has been a named investor (without lead credit) in rounds led by others, including Nervonik's $52.5M Series B (led by Amzak Health, Apr 2026), Zeto's $31M Series B (led by MindWorks Global), Abcuro's $200M Series C (led by NEA), Zenflow's $24M Series C (led by Cook Medical), and Inquis Medical's $40M Series B (led by Marshall Wace).
Recent Activity
ShangBay is actively deploying capital as of 2026. Most recent activity: Nervonik's $52.5M Series B (April 2026). In 2025, the firm backed Laplace Interventional's $22M Series C, Abcuro's $200M Series C, and Zeto's $31M Series B. 2024 was an especially active year with financings in Fluid Biomed, Zenflow, Zap Surgical, Inquis Medical, Venova Medical, and Avation Medical, plus portfolio milestones including Flare Therapeutics' Roche collaboration, Solenic Medical's AAHKS Innovation Award, and CeriBell's IPO (filed August 2024, priced October 2024).
Portfolio Highlights
ShangBay's portfolio includes 70+ companies with 9 total exits: 3 IPOs (Ceribell, Lucira Health, Apexigen, Berkeley Lights among the notable public listings/M&A) and multiple acquisitions (Arrinex by Stryker, Devoro Medical by Boston Scientific). Notable active companies include Setpoint Medical (bioelectronic medicine, presented late-breaking RESET-RA data at ACR Convergence 2024), Skyhawk Therapeutics (RNA-targeting small molecules, partnered with Ipsen), Zap Surgical (radiosurgery platform, $78M Series E), Neuro42 (FDA-cleared portable brain MRI), and Immune-Onc Therapeutics.
Team
- William Dai - Founding Managing Partner; recognized in GrowthCap's Top 25 Healthcare Investors for 2024; frequent industry commentator (LSI USA keynote coverage, April 2026)
- Chaucer Shen - Managing Partner
- Erik T. Engelson - Venture Partner
- Michael Wallace - Venture Partner
- Yajun Xu, Ph.D. - Senior Advisor
- Dr. Malcolm G. Munro - Senior Medical Advisor
- Mel Dong - Senior Advisor
- Andy Weimin Dai - Senior Advisor
- Robert Kamen - Senior Advisor
- Cindy Costello - Director of Finance & Administration
- John Dai, Olivia Sinkula, Anna Roberts - Associates
The combined leadership brings 100+ years of healthcare investing and operating experience, with deep strategic ties to medtech and pharma acquirers.
Decision Process
With two managing partners plus multiple venture partners and senior advisors (including a dedicated Senior Medical Advisor), decisions appear to run through a partnership structure informed by clinical and regulatory diligence from the firm's advisor network.
Founder Preferences
ShangBay backs technical and clinical founders solving high-severity, high-unmet-need problems, favoring teams with a credible regulatory (FDA) pathway and strong scientific/clinical founding teams rather than pure business-model innovation.
Geographic Focus
Primarily U.S.-based portfolio companies, with the firm itself headquartered in Palo Alto, CA, and network ties that support global (including Asia) market expansion and cross-border strategic partnerships.
Track Record
ShangBay has been ranked the #1 most active new device VC (2020-2023) by SVB, and #2 most-active healthcare device investor by HSBC's Venture Healthcare Report. The portfolio has generated 13 billion-dollar-plus IPOs and multiple M&A exits, with portfolio companies collectively raising roughly $1 billion in new capital across 2023-2024, including 13 portfolio companies securing financing in 2024 alone.